RICERCA ITALIANA     

FIRB simili:

• 1 - BILANCIO OSPITE-TUMORE NELLA TERAPIA MEDICA DELLE NEOPLASIE: RUOLO DI NF-kB
• 2 - Meccanismi molecolari della morte cellulare e loro implicazione in patologia umana
• 3 - Studio dell'identità cellulare e dei meccanismi di differenziazione cellulare nell'era della postegnomica utilizzando tre situazioni paradigmatiche: la mammella, l'osso e i linfociti
• 4 - Meccanismi di regolazione dello sviluppo del sistema nervoso e del differenziamento neurale (PRONEURO)
• 5 - Approcci combinati di terapia genica nel trattamento del glioblastoma
• 6 - GENOTOPO:Genomica funzionale del topo
• 7 - Riconoscimento molecolare e funzionalità cellulare
• 8 - Geni murini, fenotipi e malattie umane - MousePHD
• 9 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 10 - Interazioni funzionali tra proteine delle sinapsi: fisiopatologia e potenziali indicazioni terapeutiche

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOLOGIA APPLICATA
• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • ONCOLOGIA MEDICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Lazio

Bibliografia

 Lowe, S and Lin, AW 2000 Apoptosis in Cancer Carcinogenesis, 21,485-495
 Cai, J, and Jones, DP 1998 Superoxide in Apoptosis. J. Biol. Chem. 273, 11401-11404
 Pani, G, Bedogni, B, Anzevino, R, Colavitti, R, Palazzotti, B, Borrello, S and Galeotti, T 2000 Deregulated MnSOD expression and resistance to oxidative injury in p53 deficient cells. Cancer Res. 60, 4654-4660, 2000
 Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG. 1999 Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59:602-606
 Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, et al. 1995 Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11:376-381
 Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. 2000 Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-5


 Sgambato A, Ratto C, Faraglia B, Merico M, Ardito R, Schinzari G, Romano G, Cittadini AR.
 Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog. 1999 2:172-9.
 Orend G, Hunter T, Ruoslahti E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene. 1998 May;16(20):2575-83
 Kong S, Wei Q, Amos CI, Lynch PM, Levin B, Zong J, Frazier ML. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001 Jul 18;93(14):1106-8.
 Hirano K, Hirano M, Zeng Y, Nishimura J, Hara K, Muta K, Nawata H, Kanaide H. Cloning and functional expression of a degradation-resistant novel isoform of p27Kip1. Biochem J. 2001, 353: 51-57.
 Bahl R, Arora S, Nath N, Mathur M, Shukla NK, Ralhan R. Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene. 2000;19: 323-8.
 Sgambato A, Migaldi M, Faraglia B, Garagnani L, Romano G, De Gaetani C, Ferrari P, Capelli G, Trentini GP, Cittadini A. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 1999: 59:3245-50
 Weinstein IB, Zhou P. 1997. Cell cycle control gene defects and human cancers. . In: Bertino JR, editor. Encyclopedia of cancer, Vol. 1. New York: Academic. p 256–267.

 Winder S.J. The complexities of dystroglycan. Trends Biochem. Sci. 26, 118-124, 2001.
 Brancaccio A. Dystroglycan, a receptor for extracellular matrix proteins with a wide tissue distribution: structural and functional aspects. Biochimica in Italia 8-9, 9-21, 1998.
 Losasso, C., Di Tommaso, F., Sgambato, A., Ardito, R., Cittadini, A., Giardina, B., Petrucci, T.C. & Brancaccio, A. Anomalous dystroglycan in carcinoma cell lines. FEBS Lett. 484, 194-198, 2000.
 Sciandra, F., Schneider, M., Giardina, B., Baumgartner, S., Petrucci, T.C. & Brancaccio, A. Identification of the b-dystroglycan binding epitope within the C-terminal region of b-dystroglycan. Eur. J. Biochem. 268, 4590-4597, 2001.
 Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmüller, Engvall, E., Müller, U. & Ruegg, M.A. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413, 302-307, 2001.

 Landriscina M. et al (2001) J Biol Chem 276, 22544-22552.
 Landriscina M. et al (2000) J Biol Chem 275, 32753-32762.
 Perin M. et al (1990) Nature 345, 260-263.
 Shinshibori T. et al (1999)Biochem J 338, 583-589.
 Landriscina M., et al (2001) J Biol Chem 277, 25549-25557.

 Lindstrom JM, Acetylcholine receptors and myasthenia. Muscle Nerve. 2000, 23: 453-77.
 Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve. 1994, 17: 1393-400.
 Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986, i: 116-119.
 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptorantibodies. Nat Med. 2001, 7: 365-8.


 Abbas AK, Murphy KM, Sher A: Functional diversity of Helper T ymphocytes. Nature 1996 383:787-793
 J. C. Guèry, F. Ria, F. Galbiati, S. Smiroldo and L. Adorini: The mode of protein administration determines preferential antigen presentation by dendritic cells or B cells. Int. Immunol., 9 (1997), 9-15.
 F. Ria, G. Penna and L. Adorini: Th1 induce and Th2 cells inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur. J. Immunol. 28 (1998) 2003-2016.
 F. Aloisi, F. Ria and L. Adorini: Immunological functions of central nervous system APC: different roles for microglia and astrocytes (review). Immunol. Today 21 (2000), 141-147
 M. Rinaldi, F. Ria, P. Parrella, E. Signori, A. Serra, S.A. Ciafrè, I. Vespignani, M. Lazzari, M.G. Farace, G. Saglio, and V.M. Fazio: Antibodies elicited by naked DNA vaccination against the complementary determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinant of B-lymphoproliferative disorders specifically react with patients’ tumour cells. Cancer Res. 61 (2001), 1555-1562.
 F. Ria, P. van den Elzen, L. T. Madakamutil, J.E. Miller, E. Maverakis and E. E. Sercarz. Molecular Characterization of the T Cell Repertoire using Immunoscope Analysis and its Possible Implementation in Clinical Practice. Curr. Mol. Med. 1 (2001), 297-304

Parole Chiave

topi transgenici; carcinogenesi; angiogenesi; Distroglicano; Miastenia Grave; T cell receptor